Evidence map›Paper›PMID 17275978›Full record

ReviewProgress in neurobiology2007

N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

John R Moffett, Brian Ross, Peethambaran Arun, Chikkathur N Madhavarao, Aryan M A Namboodiri

Open access · greenAbstract readReview
In one paragraph

Review in Progress in neurobiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 696 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
696citing papers in PubMed, 10 pooled it
25.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

696 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,374 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Systematic review ofFrontiers in aging neuroscience · 2023
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

636 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

John R MoffettDepartment of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Building C, 4301 Jones Bridge Rd., Bethesda, MD 20814, USA. jmoffett@usuhs.mil
Brian Ross
Peethambaran Arun
Chikkathur N Madhavarao
Aryan M A Namboodiri
Uniformed Services University of the Health Sciences · USHuntington Medical Research Institutes · US

Funding

CANAVAN DISEASE PATHOGENESIS AND TREATMENTR01NS039387 · NINDS · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI NAMBOODIRI, ARYAN MANGALAM · 2000 to 2002
$534k
Canavan Disease: Pathogenesis and TreatmentR56NS039387 · NINDS · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI NAMBOODIRI, ARYAN MANGALAM · 2007 to 2008
$346k
NINDS NIH HHS R01 NS039387NINDS NIH HHS R01: NS39387NINDS NIH HHS R56 NS039387
6 · The paper itself

Abstract

The brain is unique among organs in many respects, including its mechanisms of lipid synthesis and energy production. The nervous system-specific metabolite N-acetylaspartate (NAA), which is synthesized from aspartate and acetyl-coenzyme A in neurons, appears to be a key link in these distinct biochemical features of CNS metabolism. During early postnatal central nervous system (CNS) development, the expression of lipogenic enzymes in oligodendrocytes, including the NAA-degrading enzyme aspartoacylase (ASPA), is increased along with increased NAA production in neurons. NAA is transported from neurons to the cytoplasm of oligodendrocytes, where ASPA cleaves the acetate moiety for use in fatty acid and steroid synthesis. The fatty acids and steroids produced then go on to be used as building blocks for myelin lipid synthesis. Mutations in the gene for ASPA result in the fatal leukodystrophy Canavan disease, for which there is currently no effective treatment. Once postnatal myelination is completed, NAA may continue to be involved in myelin lipid turnover in adults, but it also appears to adopt other roles, including a bioenergetic role in neuronal mitochondria. NAA and ATP metabolism appear to be linked indirectly, whereby acetylation of aspartate may facilitate its removal from neuronal mitochondria, thus favoring conversion of glutamate to alpha ketoglutarate which can enter the tricarboxylic acid cycle for energy production. In its role as a mechanism for enhancing mitochondrial energy production from glutamate, NAA is in a key position to act as a magnetic resonance spectroscopy marker for neuronal health, viability and number. Evidence suggests that NAA is a direct precursor for the enzymatic synthesis of the neuron specific dipeptide N-acetylaspartylglutamate, the most concentrated neuropeptide in the human brain. Other proposed roles for NAA include neuronal osmoregulation and axon-glial signaling. We propose that NAA may also be involved in brain nitrogen balance. Further research will be required to more fully understand the biochemical functions served by NAA in CNS development and activity, and additional functions are likely to be discovered.

Indexed as

Lipid MetabolismAnimalsAspartic AcidCanavan DiseaseCentral Nervous SystemEnergy MetabolismHumansMetabolic Networks and PathwaysAspartic AcidN-acetylaspartate

Identifiers

PMID17275978
PMCPMC1919520
OpenAlexW2102118295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.